http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Mingda Zhu (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Prognostic Value of the Evolution of HER2-Low Expression after Neoadjuvant Chemotherapy
Youzhao Ma,Mingda Zhu,Jingyang Zhang,Minhao Lv,Xiuchun Chen,Zhenzhen Liu 대한암학회 2023 Cancer Research and Treatment Vol.55 No.4
Purpose Patients with human epidermal growth factor receptor 2 (HER2)–low advanced breast cancer can benefit from trastuzumab deruxtecan. Given the unclear prognostic characteristics of HER2-low breast cancer, we investigated the prognostic characteristics of HER2-low expression from primary tumor to residual disease after neoadjuvant chemotherapy (NACT). Materials and Methods The data of HER2-negative patients receiving NACT at our center were collected. Pathological complete response (pCR) rate were compared between HER2-0 and HER2-low patients. The evolution of HER2 expression from primary tumor to residual disease and its impact on disease-free survival (DFS) were examined. Results Of the 690 patients, 494 patients had HER2-low status, of which 72.3% were hormone receptor (HR)–positive (p < 0.001). The pCR rates of HER2-low and HER2-0 patients (14.2% vs. 23.0%) showed no difference in multivariate analysis regardless of HR status. No association was observed between DFS and HER2 status. Of the 564 non-pCR patients, 57 (10.1%) changed to HER2-positive, and 64 of the 150 patients (42.7%) with HER2-0 tumors changed to HER2-low. HER2-low (p=0.004) and HR-positive (p=0.010) tumors before NACT were prone to HER2 gain. HER2 gain patients had a better DFS compared with HER2-negative maintained patients (87.9% vs. 79.5%, p=0.048), and the DFS of targeted therapy group was better than that of no targeted therapy group (92.4% vs. 66.7%, p=0.016). Conclusion Although HER2-low did not affect the pCR rate and DFS, significant evolution of HER2-low expression after NACT creates opportunities for targeted therapy including trastuzumab.
-
Parameterized Modeling of Spatially Varying PSF for Lens Aberration and Defocus
Wang Chao,Chen Juan,Jia Hongguang,Shi Baosong,Zhu Ruifei,Wei Qun,Yu Linyao,Ge Mingda 한국광학회 2015 Current Optics and Photonics Vol.19 No.2
Image deblurring by a deconvolution method requires accurate knowledge of the blur kernel. Existingpoint spread function (PSF) models in the literature corresponding to lens aberrations and defocus are eitherparameterized and spatially invariant or spatially varying but discretely defined. In this paper, aparameterized model is developed and presented for a PSF which is spatially varying due to lens aberrationsand defocus in an imaging system. The model is established from the Seidel third-order aberrationcoefficient and the Hu moment. A skew normal Gauss model is selected for parameterized PSF geometrystructure. The accuracy of the model is demonstrated with simulations and measurements for a defocusedinfrared camera and a single spherical lens digital camera. Compared with optical software Code V, thevisual results of two optical systems validate our analysis and proposed method in size, shape and direction. Quantitative evaluation results reveal the excellent accuracy of the blur kernel model
DBpia연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
